Kazia Therapeutics (KZA) is an oncology-focused drug development company. Its drug candidates are designed to treat diseases which are poorly served by existing therapies. In this video, James Garner, CEO, highlights the company’s business model, newest drug asset and progress over the next year.

Kazia Therapeutics Ltd's Dr James Garner speaks with Proactive at the ASX Small and Mid Cap Conference. Its lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults.